Clinical Trial News and Research

RSS

Cancer Institute of New Jersey offers COMET-2 clinical trial to examine cabozantinib drug

The Cancer Institute of New Jersey is one of 50 sites across the nation to offer a clinical trial known as COMET-2 that examines whether the drug cabozantinib is effective in reducing bone pain in patients with prostate cancer that is no longer responsive to hormone therapy and has spread (metastasized) to other parts of the body.

7 Jun 2013

Diagnoplex secures 1.3 million Swiss francs from financing round

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

7 Jun 2013

Surgeon develops new way to perform deep brain stimulation

The surgeon who more than two decades ago pioneered deep brain stimulation surgery in the United States to treat people with Parkinson's disease and other movement disorders has now developed a new way to perform the surgery - which allows for more accurate placement of the brain electrodes and likely is safer for patients.

6 Jun 2013

Echo Therapeutics to evaluate safety, efficacy of Symphony CGM System in hospital setting

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is initiating a multi-center clinical trial of its Symphony CGM System to support a CE Mark Technical File for marketing approval in Europe.

5 Jun 2013

Study: New genetic marker predicts warfarin dose in African-Americans

A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet. If confirmed in further studies, the finding may help to avert more of the bleeds and blood clots that come when a patient's starting dose misses the drug's narrow safety window.

5 Jun 2013

NeuroVive Pharmaceutical recruits first traumatic brain injury patient to evaluate NeuroSTAT

NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company´s drug candidate NeuroSTAT® for the treatment of traumatic brain injury.

5 Jun 2013

Research: 8% drop in BMI lowers risk factor for type 2 diabetes in obese teenagers

Obese teenagers who reduced their body mass index (BMI) by 8 percent or more had improvements in insulin sensitivity, an important metabolic factor related to the later development of type 2 diabetes. The teens followed a family-based, lifestyle-modification weight loss program that offers the potential to become a broader model.

5 Jun 2013

PROLOR Biotech announces initiation of hGH-CTP Phase III trial in growth hormone deficient adults

PROLOR Biotech, Inc., a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone, in growth hormone deficient adults.

4 Jun 2013

PCORI awards $2.1M to USF college of nursing to study a new approach for cancer management

The Patient-Centered Outcomes Research Institute (PCORI) has approved a $2.1-million award to the University of South Florida College of Nursing to study "Patient Outcomes of a Self-care Management Approach to Cancer Symptoms: A Clinical Trial." USF Distinguished Professor and Thompson Professor of Oncology Nursing Susan C. McMillan, PhD, ARNP, FAAN, will lead the research project.

4 Jun 2013

Duke University is awarded $2M to initiate new clinical research network on antibacterial resistance

Duke University, Durham, N.C., has been awarded $2 million to initiate a new clinical research network focused on antibacterial resistance. Total funding for the leadership group cooperative agreement award could reach up to $62 million through 2019.

4 Jun 2013

Report: 83% of cancer doctors face oncology drug shortages

Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510).

4 Jun 2013

Study examines efficacy of dietary flaxseed supplementation in management of hypercholesterolemia in children

A study by Helen Wong, R.D., of The Hospital for Sick Children, Ontario, Canada, and colleagues examined the safety and efficacy of dietary flaxseed supplementation in the management of hypercholesterolemia (high levels of cholesterol) in children.

4 Jun 2013

Vitamin C and gout: an interview with Prof. Lisa Stamp

A previous study in by Choi et al in the USA showed that people with a higher vitamin C intake have a lower risk of gout. There are also studies in healthy volunteers that suggest that vitamin C supplements reduce blood uric acid levels.

4 Jun 2013

Early detection methods can help cure cervical cancer

Cervical cancer, a disease that will affect more than 12,000 women in the United States this year and more than a half million women worldwide, leads to significantly fewer deaths when effective early detection methods are available, either via a Pap smear or with a test for presence of the human papilloma virus.

4 Jun 2013

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Precision Biologics, in collaboration with investigators from Duke University, has been selected to present an abstract of findings from its Phase 2 clinical trial at the Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

GRACE study reports colored women are poorly represented in HIV drug trials

Enrollment of women in clinical trials of new anti-HIV drugs is extremely low, representing only about 15% of all treatment-experienced patients. For women of color it is even lower.

3 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson's disease.

3 Jun 2013

Clinical Trial News and Research

Cancer Institute of New Jersey offers COMET-2 clinical trial to examine cabozantinib drug

Diagnoplex secures 1.3 million Swiss francs from financing round

Surgeon develops new way to perform deep brain stimulation

Echo Therapeutics to evaluate safety, efficacy of Symphony CGM System in hospital setting

Study: New genetic marker predicts warfarin dose in African-Americans

NeuroVive Pharmaceutical recruits first traumatic brain injury patient to evaluate NeuroSTAT

Research: 8% drop in BMI lowers risk factor for type 2 diabetes in obese teenagers

PROLOR Biotech announces initiation of hGH-CTP Phase III trial in growth hormone deficient adults

PCORI awards $2.1M to USF college of nursing to study a new approach for cancer management

Duke University is awarded $2M to initiate new clinical research network on antibacterial resistance

Report: 83% of cancer doctors face oncology drug shortages

Study examines efficacy of dietary flaxseed supplementation in management of hypercholesterolemia in children

Vitamin C and gout: an interview with Prof. Lisa Stamp

Early detection methods can help cure cervical cancer

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

GRACE study reports colored women are poorly represented in HIV drug trials

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery